1
Total investments
0
Early stage
0
Mid stage
0
Late stage
3y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Aug 2023
The Boston Chapter of the National Investor Relations Institute (NIRI Boston) is dedicated to the professional advancement of its members by supporting the Investor Relations function. NIRI Boston is committed to fostering a greater understanding of effective and ethical investor relations practices.
Experience · 3 entries
All (3)
Investments (1)
Board (1)
2023
Board Member
Aug 2023
The Boston Chapter of the National Investor Relations Institute (NIRI Boston) is dedicated to the professional advancement of its members by supporting the Investor Relations function. NIRI Boston is committed to fostering a greater understanding of effective and ethical investor relations practices.
Associate Director, Investor Relations
Jan 2023
BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules.
Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
To learn more about us, please visit www.BioNTech.com.
Our privacy statement can be found here: https://www.biontech.com/int/en/home/data-privacy-statement.html
Our imprint can be found:
https://www.biontech.com/int/en/home/imprint.html
2020
Client Lead
Feb 2020
Precision AQ - Investor Relations & External Communications (formerly Stern IR) is a premier investor relations firm, representing biotechnology companies across all market capitalizations and stages of development, and offering strategic and client-specific advisory services. For more information please visit our website at www.precisionaq.com